RXMD vs WBA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RXMD is a Hold and WBA is a StrongSell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RXMD’s FA Score shows that 1 FA rating(s) are green whileWBA’s FA Score has 1 green FA rating(s).
- RXMD’s FA Score: 1 green, 4 red.
- WBA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
WBA’s TA Score shows that 5 TA indicator(s) are bullish.
- WBA’s TA Score: 5 bullish, 5 bearish.
Price Growth
RXMD (@Drugstore Chains) experienced а 0.00% price change this week, while WBA (@Drugstore Chains) price change was -2.01% for the same time period.
The average weekly price growth across all stocks in the @Drugstore Chains industry was +1.03%. For the same industry, the average monthly price growth was +3.68%, and the average quarterly price growth was +3.61%.
Reported Earning Dates
RXMD is expected to report earnings on Aug 15, 2023.
WBA is expected to report earnings on Jan 02, 2025.
Industries' Descriptions
@Drugstore Chains (+1.03% weekly)The drugstore chains industry includes stores that sell medicines (both prescription and non-prescription), health, beauty and personal care products. Over time, many pharmacy retail chains have launched their own pharmacy benefits management services. Since demand for medical products is typically less sensitive to economic cycles, drugstore retail chains industry could be largely considered as non-cyclical. CVS Health Corporation, Walgreens Boots Alliance Inc. and Rite Aid Corporation are some of the biggest operators in this industry.
| RXMD | WBA | RXMD / WBA | |
| Capitalization | 19.7M | 18.7B | 0% |
| EBITDA | -8.77M | -11.23B | 0% |
| Gain YTD | -32.803 | -62.725 | 52% |
| P/E Ratio | 80.00 | 32.85 | 244% |
| Revenue | 10.1M | 145B | 0% |
| Total Cash | 2.23M | 668M | 0% |
| Total Debt | 3.01M | 33.6B | 0% |
RXMD | WBA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 97 | |
PRICE GROWTH RATING 1..100 | 56 | 64 | |
P/E GROWTH RATING 1..100 | 18 | 76 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
WBA's Valuation (6) in the Drugstore Chains industry is significantly better than the same rating for RXMD (78) in the null industry. This means that WBA’s stock grew significantly faster than RXMD’s over the last 12 months.
WBA's Profit vs Risk Rating (100) in the Drugstore Chains industry is in the same range as RXMD (100) in the null industry. This means that WBA’s stock grew similarly to RXMD’s over the last 12 months.
WBA's SMR Rating (97) in the Drugstore Chains industry is in the same range as RXMD (97) in the null industry. This means that WBA’s stock grew similarly to RXMD’s over the last 12 months.
RXMD's Price Growth Rating (56) in the null industry is in the same range as WBA (64) in the Drugstore Chains industry. This means that RXMD’s stock grew similarly to WBA’s over the last 12 months.
RXMD's P/E Growth Rating (18) in the null industry is somewhat better than the same rating for WBA (76) in the Drugstore Chains industry. This means that RXMD’s stock grew somewhat faster than WBA’s over the last 12 months.
| WBA | |
|---|---|
| RSI ODDS (%) | 2 days ago 73% |
| Stochastic ODDS (%) | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 52% |
| Advances ODDS (%) | 24 days ago 54% |
| Declines ODDS (%) | 10 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 45% |
RXMD and
Correlation & Price change
A.I.dvisor tells us that RXMD and PETS have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RXMD and PETS's prices will move in lockstep.
| Ticker / NAME | Correlation To RXMD | 1D Price Change % | ||
|---|---|---|---|---|
| RXMD | 100% | N/A | ||
| PETS - RXMD | 10% Poorly correlated | +35.78% | ||
| HITI - RXMD | 9% Poorly correlated | +2.26% | ||
| WBA - RXMD | 5% Poorly correlated | +0.43% | ||
| SSY - RXMD | 4% Poorly correlated | -8.35% | ||
| SAEYY - RXMD | 4% Poorly correlated | N/A | ||
More | ||||